

# Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Information for the public

Published: 15 May 2024

[www.nice.org.uk](http://www.nice.org.uk)

Tisagenlecleucel (Kymriah) is available on the NHS for people 25 years and under. It is a possible treatment for B-cell acute lymphoblastic leukaemia that is:

- relapsed after a transplant, or
- relapsed for a second or later time, or
- refractory (has not responded to treatment).

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on acute lymphoblastic leukaemia](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Anthony Nolan](#), 0303 303 0303
- [Blood Cancer UK](#), 0808 2080 888
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6134-4